CL075

CL075 (3M002) is a selective TLR8 agonist with immunomodulating properties. CL075 triggers a MyD88-dependent signaling pathway to elicit production of inflammatory cytokines and type I interferons (IFNs) via activation of NF-κB and IRF7, respectively[1][2][3].

Product Specifications

CAS Number

[256922-53-9]

Product Name Alternative

3M002

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/cl075.html

Concentration

10mM

Purity

99.25

Solubility

DMSO : 22 mg/mL (ultrasonic; warming)

Smiles

NC1=NC2=CC=CC=C2C(S3)=C1N=C3CCC

Molecular Formula

C13H13N3S

Molecular Weight

243.33

Precautions

H302, H315, H319, H335

References & Citations

[1]Lai CY, et, al. TLR7/8 agonists activate a mild immune response in rabbits through TLR8 but not TLR7. Vaccine. 2014 Sep 29;32 (43) :5593-9.|[2]Spranger S, et, al. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol. 2010 Jul 1;185 (1) :738-47.|[3]Maalej KM, et, al. TLR8, but not TLR7, induces the priming of the NADPH oxidase activation in human neutrophils. J Leukoc Biol. 2015 Jun;97 (6) :1081-7.